The 176-Year-Old Startup That Sells Science by the Milligram

In 1849, a chemist and a confectioner - two cousins from Ludwigsburg, Germany - pooled about $2,500 and set up shop in a two-story red brick house in Brooklyn. Their first product was a treatment for intestinal worms, and their competitive edge was almost comically simple: they made the medicine taste like toffee. Charles Pfizer knew chemistry; Charles Erhart knew candy. That pairing - real science, made easy to swallow - is still, 176 years later, the whole business.

Pfizer today is one of the largest pharmaceutical companies on earth. It employs roughly 75,000 people, sells products in about 175 countries, and books more than $60 billion a year. Most people met the name in 2020, when Pfizer and the German biotech BioNTech produced one of the first authorized Covid-19 vaccines and shipped it around the world at a speed the industry had never attempted. But the vaccine is not the company. It was a chapter - a very loud one - and the more interesting story is what Pfizer is doing now that the chapter has closed.

What it actually doesSelling chemistry with a moat around it

Strip away the branding and Pfizer does one thing: it turns molecules into products that a patent can protect. Discovering a drug is closer to a lottery ticket than a manufacturing line - most candidates fail in trials, and the few that work must be tested for years and cleared by regulators before anyone can sell them. What Pfizer sells is not the molecule itself, which a generic maker could eventually copy, but the whole defensible package around it: the clinical evidence, the regulatory approval, the manufacturing scale, and the patent that keeps competitors out for a fixed number of years.

That model runs across several therapy areas - vaccines, cardiology, oncology, immunology and internal medicine - and increasingly obesity. The customers are rarely the patients directly. They are governments and national health services, hospital systems, pharmacies, and the wholesalers who move product in bulk. It is a business-to-business engine that ends, eventually, at a person taking a pill or getting a shot.

The core tensionEvery blockbuster is a countdown clock

Here is the fact that explains almost every decision Pfizer makes: patents expire. When a drug loses its exclusivity, generic competitors flood in and sales can fall off a cliff - sometimes losing the bulk of their value within a couple of years. The industry even has a name for it, the "patent cliff." A company like Pfizer is therefore never finished. It is a machine that must invent, buy, or license the next blockbuster before the last one runs out.

This is why the pandemic mattered beyond the headlines. The Covid vaccine and the antiviral pill Paxlovid generated an enormous cash pile at exactly the moment several of Pfizer's older franchises were aging. The question for management became: what do you buy with a once-in-a-generation windfall? Pfizer's answer was cancer and obesity.

Products & servicesThe drugs you know, and the ones that pay the bills

Ask most people to name a Pfizer product and they will say the Covid vaccine - Comirnaty - or maybe Paxlovid, or the pill that made Pfizer famous in 1998, Viagra. But the drugs quietly carrying the company are ones the public rarely discusses. The blood thinner Eliquis, co-marketed with Bristol Myers Squibb, is one of its largest earners. The Prevnar family of pneumococcal vaccines protects against pneumonia and has sold for years. Vyndaqel and Vyndamax treat a serious heart condition. This is the lesson buried in every big pharmaceutical company: the products you have heard of are seldom the ones paying the rent.

The newest additions come from the checkbook. In 2023 Pfizer bought Seagen for roughly $43 billion, acquiring a set of targeted cancer therapies known as antibody-drug conjugates - essentially guided missiles that deliver toxic payloads to tumor cells. In 2025 it agreed to acquire Metsera, adding obesity and metabolic-disease assets including berobenatide, an ultra-long-acting GLP-1 - the drug class behind the weight-loss boom led by Novo Nordisk and Eli Lilly. Pfizer, in other words, has decided it wants a seat at both of the decade's biggest tables.

How it is differentScale is the strategy

Pfizer's rivals - Merck, Johnson & Johnson, AbbVie, Novartis, Roche, AstraZeneca, Eli Lilly, Novo Nordisk and others - are all playing versions of the same game. What distinguishes Pfizer is less a single breakthrough than sheer scale and the willingness to spend it. When the world needed a vaccine made in the billions of doses, Pfizer's manufacturing muscle was the differentiator, not just the science. The same story runs through its history: during the Civil War it supplied the Union Army; in the 1940s it mastered deep-tank fermentation to mass-produce penicillin; for decades it was the world's largest producer of citric acid. Being the one who can make it, at scale, when everyone needs it, is a recurring Pfizer theme.

The reinventionRepositioning a 176-year-old brand

A company this old carries baggage - and after the pandemic, Pfizer's public image was more tangled than ever. Part of the current chapter is a deliberate marketing reset. Under Global Chief Marketing Officer Susan Rienow, a 20-plus-year Pfizer veteran who took the role in 2024, the company has leaned into oncology as its public identity, including a cancer-themed Super Bowl advertisement. The message underneath the spots is strategic: Pfizer would like the world to stop thinking of it as "the Covid vaccine company" and start thinking of it as a cancer company, an obesity company, a company with a pipeline.

That pipeline is the real product for investors. For 2026, Pfizer has framed the year as a pivot from Covid to execution, pointing to roughly 20 pivotal study starts, a series of key clinical data readouts, and several regulatory decisions - a heavy concentration in obesity and oncology. In its most recent quarter it topped Wall Street estimates and raised the low end of its revenue guidance, crediting growth from newer and acquired products.

Where it fitsThe old giant in a fast market

Pfizer sits near the top of an industry defined by long timelines, high failure rates, and enormous payoffs. Its edge is a combination of research capacity, global manufacturing, deep pockets for acquisitions, and a distribution reach that few can match. Its challenge is the same one it has faced for a century and a half: keep the pipeline fuller than the patent cliff can empty it. The Brooklyn worm medicine is long gone. The formula behind it - real science, made easy to take, protected long enough to profit - is exactly the machine still running today.